Analysis

Hoth Therapeutics, Inc. (HOTH) Stock Analysis

Hoth Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to HOTH.

websiteHOTH/analysis/HOTH

Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to HOTH.

Stock profile

Ticker

HOTH

Asset type

Stock

Market cap

$13.2M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Hoth Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • HOTH primary listing

Latest Hoth Therapeutics, Inc. news

Hoth Therapeutics : Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastruc...

Hoth Therapeutics : Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic

Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology

AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acq...

AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Gen...

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER ...

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activa...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research ...

Research sections

Valuation

Review valuation context for Hoth Therapeutics, Inc..

Future growth

Review future growth context for Hoth Therapeutics, Inc..

Past performance

Review past performance context for Hoth Therapeutics, Inc..

Financial health

Review financial health context for Hoth Therapeutics, Inc..

Dividend

Review dividend context for Hoth Therapeutics, Inc..

Management

Review management context for Hoth Therapeutics, Inc..

Ownership

Review ownership context for Hoth Therapeutics, Inc..

Other information

Review other information context for Hoth Therapeutics, Inc..

Community

Review community context for Hoth Therapeutics, Inc..